The North America Multiplex Assays Market, valued at USD 2,430 Million in 2025, is expected to reach USD 7,220 Million by 2035, expanding at a CAGR of 10.8% from 2024 to 2035. The market is driven by technological advancements and increasing adoption in clinical diagnostics, fueling growth across key regions including the United States, Canada, and Mexico.
The economic impact of tariffs on "North America Multiplex Assays Market".
Market Growth Drivers
Technological Advancements in Multiplexing Platforms: Leading companies such as Luminex Corporation (now a part of DiaSorin) have been at the forefront of developing highly sensitive and efficient multiplex assays. These technological improvements have enabled simultaneous detection and quantification of multiple biomarkers with greater accuracy and speed, catering to hospitals, research institutions, and biopharmaceutical companies. The integration of automation and digital platforms has further eased workflow bottlenecks, reducing turnaround times for critical diagnostic and research purposes. These advances support precision medicine, ensuring that market demand remains strong.
Rising Demand for Biomarker-based Diagnostics: The surge in chronic and infectious diseases in North America has amplified the need for accurate, multi-analyte diagnostic solutions. Companies like Thermo Fisher Scientific have expanded their multiplex assay portfolios to address oncology, autoimmune, and infectious disease markets. The ability to run comprehensive panels from limited patient samples improves diagnostic efficiency and enhances patient care. The growing emphasis on personalized medicine, particularly in cancer and immunology, continuously drives investments and commercial interest in multiplex assays across North America.
Market Trends
Integration of Artificial Intelligence and Data Analytics: Companies such as Bio-Rad Laboratories are increasingly incorporating artificial intelligence (AI) and advanced data analytics into their multiplex assay workflow software. These solutions help in analyzing large panels of data swiftly, identifying biomarker patterns, and generating actionable clinical insights. The use of AI-based analytics enhances accuracy, improves workflow efficiency, and supports complex data interpretation, aiding in drug discovery and personalized therapy development.
Growing Adoption in Clinical Diagnostics and Drug Discovery: The utilization of multiplex assays is rapidly expanding in clinical labs and pharmaceutical R&D, especially due to the COVID-19 pandemic’s impact on laboratory testing requirements. Firms such as Merck KGaA have broadened their product offerings to meet the demand for high-throughput testing and comprehensive patient screening. Multiplex technology is being increasingly adopted for companion diagnostics in oncology and infectious disease, enabling earlier intervention and monitoring of therapeutic effectiveness.
Market Opportunities
Expansion into Emerging Application Areas: Companies such as Quanterix are pursuing opportunities to use multiplex assays for early Alzheimer’s detection and monitoring neurodegenerative diseases. The growing demand for early diagnostic solutions provides significant revenue potential.
Collaborative Research and Development Initiatives: Strategic partnerships between diagnostic firms and academic institutions are creating opportunities for innovation in multiplex biomarker discovery and validation, enabling the development of novel, clinically relevant panels for unmet diagnostic needs.
North America Multiplex Assays Market Revenue (USD Million), 2020-2035
The chart illustrates steady market growth for North America Multiplex Assays from 2020 to 2035. The market shown starts at USD 1,280 Million in 2020, growing with a CAGR of 10.8%. Key inflection points include increased adoption of multiplex assays post-COVID-19 (2021-2023) and technological advancements accelerating growth through 2030 and beyond, reaching an estimated USD 7,220 Million in 2035. This robust upward trend reflects ongoing R&D, expansion of clinical applications, and strong demand for precision diagnostics across the region, making North America a leader in the global multiplex assays landscape.
North America Multiplex Assays Market Share by Region (%), 2025
The 2025 regional share pie chart shows the United States leading with 74% market share, reflecting its advanced healthcare infrastructure and greater R&D investments. Canada follows with 15%, benefiting from growing biopharma activity and government support. Mexico holds 6%, leveraging its increasing healthcare modernization efforts. The remaining 5% is distributed among the Rest of North America, including Caribbean and Central American territories, which are gradually adopting new diagnostic technologies. The dominance of the US is underpinned by the presence of leading players, significant funding, and faster regulatory approvals compared to other North American regions.
Recent Developments in North America Multiplex Assays Market (Past 6 Months)
In April 2024, DiaSorin (following the Luminex acquisition) launched the xMAP INTELLIFLEX DR-SE, a new flow cytometry-based multiplexing system, expanding throughput and enhancing clinical diagnostic capabilities for infectious and genetic disease applications in North America.
In May 2024, Bio-Rad Laboratories released the Bio-Plex Pro Human Cytokine Screening Panel 48-plex, supporting comprehensive immune response monitoring in clinical and translational research, catering to the growing demand for COVID-19 and oncology biomarker analysis.
In March 2024, Thermo Fisher Scientific announced a collaboration with Mayo Clinic’s biomarker discovery group to co-develop novel multiplex immunoassays for neurodegenerative diseases, bringing advanced multiplex technology one step closer to routine clinical practice in the region.
Press Releases